Ftse Mib
38.456,17
0,09%
DAX
22.425,93
0,73%
S&P 500
6.028,00
0,25%
NASDAQ
19.471,05
-0,27%
Bitcoin
94.785,02
-1,55%
Pepperstone
Advertisement
Registration Strip Icon for alerts Registrati per avvisi in tempo reale, portafoglio personalizzato e movimenti di mercato.
Registrati

Quotazioni in diretta

Non abbiamo trovato risultati per:
Assicurati di aver scritto correttamente o prova ad allargare la ricerca.

Più Attivi

Toplist

Sembra che tu non sia connesso.
Clicca il pulsante qui sotto per accedere e visualizzare la tua cronologia recente.

Registrati

Sei già registrato? Accedi

Pepperstone

Inizia Ora

Pepperstone
Home Investire Azioni U.S.A. AMEX OS Therapies Incorporated (OSTX) OS Therapies Incorporated (OSTX) Notizie

OS Therapies Incorporated

OSTX
1,7594
0,0594 (3,49%)
Ultimo aggiornamento: 19:00:49
Dati in Delay di 15 minuti
Borsa: AMEX
Tipo: Azione
Valuta: USD

Ultime notizie

Data Ora Fonte Titolo
24/2/202513:25BWOS Therapies Forms Subsidiary OS Drug Conjugates and..
20/2/202511:00BWOS Therapies Receives Patent Notice of Allowance from U.S...
19/2/202503:00EDGAR2Form 4 - Statement of changes in beneficial ownership of..
14/2/202522:26EDGAR2Form 5 - Annual statement of changes in beneficial ownership..
14/2/202513:36BWOS Therapies Initiates Commercial-ready Manufacturing of..
07/2/202523:23EDGAR2Form PRE 14A - Other preliminary proxy statements
04/2/202513:33BWOS Therapies Provides Corporate Update
31/1/202522:22EDGAR2Form S-1 - General form for registration of securities under..
29/1/202516:05BWOS Therapies Agrees to Acquire All Listeria..
29/1/202515:27EDGAR2Form 8-K - Current report
29/1/202515:22BWOS Therapies Agrees to Acquire All Listeria..
18/1/202501:47EDGAR2Form SCHEDULE 13D - General Statement of Acquisition of..
18/1/202501:00EDGAR2Form 4 - Statement of changes in beneficial ownership of..
15/1/202522:52EDGAR2Form 8-K - Current report
15/1/202515:17BWOS Therapies Announces Phase 2b Clinical Trial of OST-HER2..
15/1/202513:40BWOS Therapies Announces Phase 2b Clinical Trial of OST-HER2..
15/1/202502:26EDGAR2Form 4 - Statement of changes in beneficial ownership of..
14/1/202522:56EDGAR2Form 8-K - Current report
13/1/202515:26EDGAR2Form S-8 - Securities to be offered to employees in employee..
03/1/202523:27EDGAR2Form S-1/A - General form for registration of securities..
03/1/202523:21EDGAR2Form 8-K - Current report
02/1/202517:16BWOS Therapies to Attend the 43rd Annual J.P. Morgan..
31/12/202421:38BWOS Therapies Announces Closing of $6 Million Private..
30/12/202423:28EDGAR2Form 8-K - Current report
26/12/202416:01BWOS Therapies Partners with B2i Digital to Engage with..
24/12/202415:32BWOS Therapies Announces Pricing of $6 Million Private..
15/11/202422:05EDGAR2Form 8-K - Current report
15/11/202415:47BWOS Therapies Reports Third Quarter 2024 Financial Results..
15/11/202415:14EDGAR2Form 10-Q - Quarterly report [Sections 13 or 15(d)]
14/11/202422:58EDGAR2Form NT 10-Q - Notification of inability to timely file Form..
04/11/202413:00BWOS Therapies to Present at The Spartan Capital Investor..
01/11/202422:00EDGAR2Form 8-K - Current report
30/10/202413:51BWJoin OS Therapies’ Exclusive Live Investor Webinar and Q&A..
28/10/202421:55EDGAR2Form 8-K - Current report
28/10/202421:44BWOS Therapies Appoints Two Bio-Pharmaceutical Industry..
24/10/202414:46BWOS Therapies to Present at the LD Micro Main Event XVII
17/10/202415:22BWOS Therapies to Participate in a Fireside Chat at the 2024..
03/10/202414:00BWOS Therapies Announces Last Patient Enrolled in OST-HER2..
13/9/202414:09BWOS Therapies Announces Development of Two Novel Tunable..
05/9/202414:22BWOS Therapies to Present at H.C. Wainright 26th Annual Global..
29/8/202413:53BWOS Therapies Announces Last Patient Enrolled in OST-HER2..
22/8/202414:00BWOS Therapies Appoints Borys Shor, PhD to ADC Advisory Board
22/8/202412:00BWOS Therapies Clarifies CUSIP of Common Stock
19/8/202414:30BWOS Therapies Accepted Into Johnson & Johnson Innovation -..
02/8/202414:55BWOS Therapies Forms Osteosarcoma Patient Advocacy Advisory..
01/8/202400:21BWOS Therapies Announces Pricing of its Initial Public..
30/7/202420:29EDGAR2Form 8-A12B - Registration of securities [Section 12(b)]
24/7/202416:48BWOS Therapies Announces Positive Safety Data from Phase 1..
03/6/202418:44BWOS Therapies Announces Positive Clinical Update from Ongoing..
Apertura: 1,79 Min: 1,75 Max: 1,80
Chiusura: 1,70

La tua Cronologia

AMEX
OSTX
OS Therapies
Delayed Upgrade Clock

Il sito ADVFN Italia è stato realizzato ed è gestito da PRODESFIN su licenza di ADVFN PLC.

PER CONTATTI E PUBBLICITA' SUL SITO CLICCARE QUI

Accedendo ai servizi offerti da ADVFN, ne si accettano le condizioni generali Termini & Condizioni

ADVFN Network

Rimuovi gli annunci

Iscriviti per un'esperienza senza pubblicità

Nessuna pubblicità

Prova adesso

Conserva gli annunci